Selinexor population pharmacokinetic and exposure –response analyses to support dose optimization in patients with diffuse large B-cell lymphoma

ConclusionsSimulations of the safety and efficacy ER models suggested that, compared to a starting dose of 60  mg twice weekly (BIW), a 40 mg BIW regimen resulted in an absolute decrease in AE probabilities between 1.9 and 5.3%, with a clinically significant absolute efficacy decrease of 4.7% in ORR. The modeling results support that 60 mg BIW is the optimal dose in patients with DLBCL.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research